(Q34375028)

English

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

0 references

1 reference

based on heuristic

inferred from title

Yvonne Vergouwe

9

object named as

Yvonne Vergouwe

0 references

André B Rietman

object named as

André B Rietman

3

0 references

Henriette A Moll

13

object named as

Henriëtte A Moll

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

author name string

Thijs van der Vaart

1

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ellen Plasschaert

2

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Marleen Renard

4

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Rianne Oostenbrink

5

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Annick Vogels

6

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Marie-Claire Y de Wit

7

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Mie-Jef Descheemaeker

8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Yvonne Vergouwe

9

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Coriene E Catsman-Berrevoets

10

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Eric Legius

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Ype Elgersma

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

publication date

1 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Lancet Neurology

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

1076-1083

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and management of individuals with neurofibromatosis 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The nature and frequency of cognitive deficits in children with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of neurofibromatosis type 1 on school performance.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of executive function and attention in children with neurofibromatosis type 1: Relationships between cognitive measures and real-world behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuropsychological profile in adults with neurofibromatosis type 1 compared to a control group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurofibromin regulation of ERK signaling modulates GABA release and learning

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Neurofibromin regulates corticostriatal inhibitory networks during working memory performance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lovastatin regulates brain spontaneous low-frequency brain activity in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinically relevant differences between the statins: implications for therapeutic selection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of ADHD in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Music lessons enhance IQ.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A mouse model for the learning and memory deficits associated with neurofibromatosis type I

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of a novel computerized task to assess spatial learning in children and adolescents with neurofibromatosis type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

GABA deficit in the visual cortex of patients with neurofibromatosis type 1: genotype-phenotype correlations and functional impact

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2813%2970227-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1474-4422(13)70227-8

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34375028&oldid=1982143520"